ImmunocoreIMCR
About: Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.
Employees: 497
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
34% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 35
0.42% more ownership
Funds ownership: 90.05% [Q2] → 90.47% (+0.42%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
5% less capital invested
Capital invested by funds: $1.49B [Q2] → $1.41B (-$80.7M) [Q3]
7% less funds holding
Funds holding: 135 [Q2] → 126 (-9) [Q3]
27% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 26
56% less call options, than puts
Call options by funds: $6.62M | Put options by funds: $15M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Needham Gil Blum 23% 1-year accuracy 38 / 165 met price target | 134%upside $71 | Buy Reiterated | 10 Jan 2025 |
Morgan Stanley Andrew Galler 0% 1-year accuracy 0 / 1 met price target | 15%upside $35 | Equal-Weight Downgraded | 13 Dec 2024 |
Mizuho Graig Suvannavejh 50% 1-year accuracy 15 / 30 met price target | 25%upside $38 | Neutral Downgraded | 11 Nov 2024 |
UBS David Dai 18% 1-year accuracy 2 / 11 met price target | 21%downside $24 | Sell Initiated | 24 Oct 2024 |
HC Wainwright & Co. Patrick Trucchio 34% 1-year accuracy 53 / 158 met price target | 229%upside $100 | Buy Reiterated | 24 Oct 2024 |
Financial journalist opinion
Based on 9 articles about IMCR published over the past 30 days